Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
SYSCHEM (I). TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
SYSCHEM (I). Mar-23 |
TEVA PHARMA Dec-13 |
SYSCHEM (I)./ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 65 | 3,479 | - | |
Low | Rs | 11 | 3,022 | - | |
Sales per share (Unadj.) | Rs | 30.3 | 1,996.4 | - | |
Earnings per share (Unadj.) | Rs | 1.4 | 124.7 | - | |
Cash flow per share (Unadj.) | Rs | 2.3 | 286.1 | - | |
Dividends per share (Unadj.) | Rs | 0 | 109.18 | - | |
Avg Dividend yield | % | 0 | 3.4 | 0.0% | |
Book value per share (Unadj.) | Rs | 7.0 | 2,217.6 | - | |
Shares outstanding (eoy) | m | 31.89 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.3 | 1.6 | 77.3% | |
Avg P/E ratio | x | 27.0 | 26.1 | 103.5% | |
P/CF ratio (eoy) | x | 16.9 | 11.4 | 148.4% | |
Price / Book Value ratio | x | 5.5 | 1.5 | 372.2% | |
Dividend payout | % | 0 | 87.5 | 0.0% | |
Avg Mkt Cap | Rs m | 1,217 | 2,756,220 | 0.0% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 44 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,667.6 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,353.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 967 | 1,692,969 | 0.1% | |
Other income | Rs m | 2 | 0 | - | |
Total revenues | Rs m | 970 | 1,692,969 | 0.1% | |
Gross profit | Rs m | 86 | 463,620 | 0.0% | |
Depreciation | Rs m | 27 | 136,844 | 0.0% | |
Interest | Rs m | 0 | 33,253 | 0.0% | |
Profit before tax | Rs m | 62 | 293,523 | 0.0% | |
Minority Interest | Rs m | 0 | 1,333 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -192,682 | -0.0% | |
Tax | Rs m | 16 | -3,584 | -0.5% | |
Profit after tax | Rs m | 45 | 105,758 | 0.0% | |
Gross profit margin | % | 8.9 | 27.4 | 32.6% | |
Effective tax rate | % | 26.6 | -1.2 | -2,180.6% | |
Net profit margin | % | 4.7 | 6.2 | 74.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 586 | 1,143,425 | 0.1% | |
Current liabilities | Rs m | 430 | 997,163 | 0.0% | |
Net working cap to sales | % | 16.1 | 8.6 | 186.6% | |
Current ratio | x | 1.4 | 1.1 | 118.8% | |
Inventory Days | Days | 4 | 91 | 4.4% | |
Debtors Days | Days | 1,582 | 96 | 1,649.9% | |
Net fixed assets | Rs m | 319 | 552,961 | 0.1% | |
Share capital | Rs m | 319 | 4,167 | 7.7% | |
Net worth | Rs m | 223 | 1,880,567 | 0.0% | |
Long term debt | Rs m | 16 | 865,653 | 0.0% | |
Total assets | Rs m | 904 | 3,868,976 | 0.0% | |
Interest coverage | x | 147.5 | 9.8 | 1,500.5% | |
Debt to equity ratio | x | 0.1 | 0.5 | 15.6% | |
Sales to assets ratio | x | 1.1 | 0.4 | 244.5% | |
Return on assets | % | 5.0 | 3.6 | 140.2% | |
Return on equity | % | 20.2 | 5.6 | 359.8% | |
Return on capital | % | 25.9 | 4.9 | 525.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | -85 | 269,772 | -0.0% | |
From Investments | Rs m | 91 | -95,591 | -0.1% | |
From Financial Activity | Rs m | NA | -323,609 | 0.0% | |
Net Cashflow | Rs m | 5 | -149,429 | -0.0% |
Compare SYSCHEM (I). With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare SYSCHEM (I). With: BLISS GVS PHARMA WYETH SANJIVANI PA AMRUTANJAN HEALTHCARE DIVIS LABORATORIES
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.